Funder
National Natural Science Foundation of China
Subject
Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry
Reference21 articles.
1. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth;Yakes;Mol. Cancer Ther.,2011
2. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer;You;Cancer Res.,2011
3. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer;Bentzien;Thyroid,2013
4. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer;Kurzrock;J. Clin. Oncol.,2011
5. Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): results from a phase II randomized discontinuation trial (RDT);Winer;J. Clin. Oncol.,2012
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献